Exbio — Research products — Antibodies — Cytoskeleton and ECM — Anti-Hu Tenascin C Purified

Anti-Hu Tenascin C Purified

Regulatory status

RUO

Antigen

Tenascin C

Clone

T2H5

Format

Purified

Reactivity

Human

Application

IP, WB, IHC(P)

Variant

0.1 mg

11-370-C100

In stock

165.00 USD

0.025 mg

11-370-C025

Delivery 1 week

82.50 USD

Variant

0.1 mg

11-370-C100

In stock

165.00 USD

0.025 mg

11-370-C025

Delivery 1 week

82.50 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG1

Specificity

The antibody T2H5 recognizes tenascin C, a large hexameric extracellular matrix glycoprotein.

Application

IP, WB, IHC(P)

Application details

Immunohistochemistry (paraffin sections): Immunohistochemical detection of tenascin is valuable for studies of tissue differentiation and tumour growth. The antibody T2H5 is excellent for staining of paraffin-embedded tissue sections. Heat-mediated antigen retrieval in citrate buffer.
Western blotting: Recommended dilution: 1-2 μg/ml.

Reactivity

Human

Immunogen

Protein preparation from a homogenate of a human mammary tumour specimen.

Concentration

1 mg/ml

Preparation

Purified by protein-A affinity chromatography.

Formulation

Tris buffered saline (TBS), pH 8.0, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

TNC, Hexabrachion, Cytotactin, Neuronectin

Antigen description

Tenascin C is an approximately 250 kDa extracellular matrix glycoprotein with important roles in the nervous system, as it promotes correct migration of growing axons during development and during neuronal regeneration. It is also involved in synaptic plasticity. Ligands of tenascin C are integrins alpha-8/beta-1, alpha-9/beta-1, alpha-V/beta-3, and alpha-V/beta-6. Similarly to neural cells, it also stimulates angiogenesis by promoting elongation and migration of endothelial cells.

Entrez Gene ID 3371

UniProt ID P24821

Immunohistochemistry staining of tonsil (paraffin-embedded sections) with anti-human tenascin C (T2H5).

Separation of U-87 MG cells stained using anti-tenascin C (T2H5) purified antibody (concentration in sample 12 μg/ml, GAM FITC, red-filled) from U-87 MG cells unstained by primary antibody (GAM FITC, black-dashed) in flow cytometry analysis (surface staining).

Immunocytochemistry staining of tenascin C in U-87 MG cells using purified mouse monoclonal antibody T2H7 (concentration in sample 12 μg/ml, GAM FITC, right picture) vs. Hoechst 34580 nuclear staining (left picture).

Western blotting analysis of human tenascin C using mouse monoclonal antibody T2H5 on lysates of U87-MG cell line and Jurkat cell line (tenascin non-expressing cell line; negative control) under non-reducing and reducing conditions. Cells were lysed by 50 mM TRIS-Cl pH 6.6, 4M urea, 4% SDS, samples were mixed and heated (100°C, 5 min) with reducing and non-reducing SDS-loading buffer, then resolved using 7.5% Tris-glycine SDS gel electrophoresis. Nitrocellulose membrane was probed with 2 µg/ml of mouse anti-tenascin monoclonal antibody followed by IRDye800-conjugated anti-mouse secondary antibody. Tenascin C was detected slightly above 250 kDa.

Product specific references:

Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, Agnantis NJ, Pavlidis N: Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer. 2002 Dec;38(18):2362-70.
PubMed

Gulubova M: Immunohistochemical localization of collagen type III and type IV, laminin, tenascin and alpha-smooth muscle actin (alphaSMA) in the human liver in peliosis. Pathol Res Pract. 2002;198(12):803-12.
PubMed

Faustino AM, van Garderen E, Schalken JA, Nederbragt H: Tenascin expression in normal, hyperplastic, dysplastic and neoplastic canine mammary tissues. J Comp Pathol. 2002 Jan;126(1):1-8.
PubMed

Tokes AM, Hortovanyi E, Csordas G, Kulka J, Mozes G, Hatalyak A, Kadar A: Immunohistochemical localisation of tenascin in invasive ductal carcinoma of the breast. Anticancer Res. 1999 Jan-Feb;19(1A):175-9.
PubMed

Bhattacharyya S, Wang W, Morales-Nebreda L, Feng G, Wu M, Zhou X, Lafyatis R, Lee J, Hinchcliff M, Feghali-Bostwick C, Lakota K, Scott Budinger GS, Raparia K, Tamaki Z, Varga J: Tenascin-C drives persistence of organ fibrosis. Nat Commun. 2016 Jun 3;7:11703
PubMed

Seyger MM, van Bruggen MC, Hardeman HK, van den Hoogen FH, Berden JH, van den Born J, de Jong EM: Decreased staining of heparan sulfate in non-lesional skin of a subgroup of patients with systemic lupus erythematosus. Acta Derm Venereol. 1998 Sep;78(5):326-30.
PubMed

Le Poole IC, van den Wijngaard RM, Westerhof W, Das PK: Tenascin is overexpressed in vitiligo lesional skin and inhibits melanocyte adhesion. Br J Dermatol. 1997 Aug;137(2):171-8
PubMed

Verstraeten AA, Mackie EJ, Hageman PC, Hilgers J, Schol DJ, de Jongh GJ, Schalkwijk J: Tenascin expression in basal cell carcinoma. Br J Dermatol. 1992 Dec;127(6):571-4
PubMed

Mansour RG, Stamper L, Jaeger F, McGuire E, Fouda G, Amos J, Barbas K, Ohashi T, Alam SM, Erickson H, Permar SR: The presence and anti-HIV-1 function of tenascin C in breast milk and genital fluids. PLoS One. 2016 May 16;11(5):e0155261.
PubMed

Latijnhouwers MA, Bergers M, Kuijpers AL, van der Vleuten CJ, Dijkman H, van de Kerkhof PC, J Schalkwijk: Tenascin-C is not a useful marker for disease activity in psoriasis. Acta Derm Venereol. 1998 Sep;78(5):331-4.
PubMed

Schalkwijk J, Zweers MC, Steijlen PM, Dean WB, Taylor G, van Vlijmen IM, van Haren B, Miller WL, Bristow J: A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X deficiency. N Engl J Med. 2001 Oct 18;345(16):1167-75.
PubMed